PHA Classroom banner

PHA Classroom has moved! Visit

>> Back to Recordings
Session Recording from PHA's 2010 9th International PH Conference

Infused Prostacyclins

June 26, 2010 

Infused epoprostenol was the first therapy approved by the FDA for the treatment of pulmonary arterial hypertension. Prostacylins are among the most potent and effective therapies for patients with advanced pulmonary arterial hypertension. However, there are side effects and complications of these therapies due to their unique delivery systems. This session will review the data with the multiple infused prostacylins currently available, focusing on patient selection and management of side effects and complications.

View session handout (PDF)

The below recording will begin automatically. To view the controls, move your mouse anywhere over the video then move to the control interface at the bottom of the video.

Presenter Information

Vallerie McLaughlin, MD; University of Michigan, Ann Arbor, Mich. (Chair)  
Robert Frantz, MD; Mayo Clinic, Rochester, Minn.
Richard Channick, MD, Massachusetts General Hospital, Boston, Mass.
Crystal Weber, RN; Duke University, Durham, N.C.

>>If you liked this recording, you may enjoy New Medical Therapies for Children with PH

New Medical Therapies for Children with PH panelists





Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. Bayer HealthCare United Therapeutics Corporation
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.


FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2016 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.